المؤلفون: Ekaterina K. Kulbachinskaya, Vera V. Bereznitskaya, Е. К. Кульбачинская, В. В. Березницкая

المساهمون: Not specified., Отсутствует.

المصدر: Current Pediatrics; Том 23, № 2 (2024); 63-70 ; Вопросы современной педиатрии; Том 23, № 2 (2024); 63-70 ; 1682-5535 ; 1682-5527

مصطلحات موضوعية: имплантируемый кардиовертер-дефибриллятор, atenolol, propafenone, primary channelopathy, sudden cardiac death, left side sympathectomy, implantable cardioverter defibrillator, атенолол, пропафенон, первичная каналопатия, внезапная сердечная смерть, левосторонняя симпатэктомия

وصف الملف: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3449/1364; Pflaumer A, Davis AM. An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2019;28(3):366–369. doi: https://doi.org/10.1016/j.hlc.2018.10.016; Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. doi: https://doi.org/10.1093/eurheartj/ehac262; Kurtzwald-Josefson E, Hochhauser E, Katz G, et al. Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice. J Appl Physiol (1985). 2012;113(11):1677–1683. doi: https://doi.org/10.1152/japplphysiol.00818.2012; Ostby SA, Bos JM, Owen HJ, et al. Competitive Sports Participation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center’s Early Experience. JACC Clin Electrophysiol. 2016;2(3):253–262. doi: https://doi.org/10.1016/j.jacep.2016.01.020; Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867l. doi: https://doi.org/10.1093/eurheartj/ehv316; Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41–e44. doi: https://doi.org/10.1016/j.hrthm.2016.09.012; Leren IS, Saberniak J, Majid E, et al. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016;13(2):432–440. doi: https://doi.org/10.1016/j.hrthm.2015.09.029; Peltenburg PJ, Kallas D, Bos JM, et al. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2022;145(5):333–344. doi: https://doi.org/10.1161/CIRCULATIONAHA.123.064786; Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119(18):2426–2434. doi: https://doi.org/10.1161/CIRCULATIONAHA.108.829267; Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic Polymorphic Ventricular Tachycardia in Children: Analysis of Therapeutic Strategies and Outcomes from an International Multicenter Registry. Circ Arrhythm Electrophysiol. 2015;8(3):633–642. doi: https://doi.org/10.1161/CIRCEP.114.002217; Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89(1):66–70. doi: https://doi.org/10.1136/heart.89.1.66; Березницкая В.В., Кульбачинская Е.К., Школьникова М.А. Особенности клинических проявлений и эффективность антиаритмической терапии у больных с катехоламинергической полиморфной желудочковой тахикардией // Вестник аритмологии. — 2021.—Т.28.—№4.—С.62–69.—doi:https://doi.org/10.35336/VA-2021-4-62-69; Кульбачинская Е.К., Березницкая В.В. CASQ2: клинико-генетические особенности катехоламинергической полиморфной желудочковой тахикардии в трех семьях // Альманах клинической медицины. — 2023. — Т. 51. — № 3. — С. 192–199. — doi: https://doi.org/10.18786/2072-0505-2023-51-022; Mazzanti A, Kukavica D, Trancuccio A, et al. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers. JAMA Cardiol. 2022;7(5):504–512. doi: https://doi.org/10.1001/jamacardio.2022.0219; Veith M, El-Battrawy I, Roterberg G, et al. Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Clin Med. 2020;9(4):903. doi: https://doi.org/10.3390/jcm9040903; Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69–74. doi: https://doi.org/10.1161/01.cir.0000020013.73106.d8; Marai I, Khoury A, Suleiman M, et al. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. Am J Cardiol. 2012;110(1):72–76. doi: https://doi.org/110.1016/j.amjcard.2012.02.049; Kawata H, Ohno S, Aiba T, et al. Catecholaminergic polymorphic ventricular tachycardia (CPVT) associated with ryanodine receptor (RyR2) gene mutations: Long-term prognosis after initiation of medical treatment. Circ J. 2016;80(9):1907–1915. doi: https://doi.org/10.1253/circj.CJ-16-0250; Li Y, Peng X, Lin R, et al. The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia. Front Physiol. 2022;13:850117. doi: https://doi.org/10.3389/fphys.2022.850117; Salvage SC, Huang CL, Fraser JA, Dulhunty AF. How does flecainide impact RyR2 channel function? J Gen Physiol. 2022;154(9): e202213089. doi: https://doi.org/10.1085/jgp.202213089; Bannister ML, MacLeod KT, George CH. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor. Br J Pharmacol. 2022;179(11):2558–2563. doi: https://doi.org/10.1111/bph.15718; Kryshtal DO, Blackwell DJ, Egly CL, et al. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT. Circ Res. 2021;128(3):321–331. doi: https://doi.org/10.1161/CIRCRESAHA.120.316819; Kannankeril PJ, Moore JP, Cerrone M, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia a randomized clinical trial. JAMA Cardiology. 2017;2(7):759–766. doi: https://doi.org/10.1001/jamacardio.2017.1320; Khoury A, Marai I, Suleiman M, et al. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013;10(11):1671–1675. doi: https://doi.org/10.1016/j.hrthm.2013.08.011; Watanabe H, Van Der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013;10(4):542–547. doi: https://doi.org/10.1016/j.hrthm.2012.12.035; Jacquemart C, Ould Abderrahmane F, Massin MM. Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia. J Electrocardiol. 2012;45(6):736–738. doi: https://doi.org/10.1016/j.jelectrocard.2012.05.002; Pott C, Dechering DG, Reinke F, et al. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: A case report and review of the current literature. Europace. 2011;13(6):897–901. doi: https://doi.org/10.1093/europace/euq517; Padfield GJ, AlAhmari L, Lieve KV, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of beta-blockade. Heart Rhythm. 2016;13(2):609–613. doi: https://doi.org/10.1016/j.hrthm.2015.09.027; Savio-Galimberti E, Knollmann BC. Channel activity of cardiac ryanodine receptors (RyR2) determines potency and efficacy of flecainide and R-propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes. PLoS One. 2015;10(6):e0131179. doi: https://doi.org/10.1371/journal.pone.0131179; Marx A, Lange B, Nalenz C, et al. A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Reports. 2019;5(2):74–77. doi: https://doi.org/10.1016/j.hrcr.2018.04.003; Li S, Lv T, Yang J, et al. A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia. Clin Exp Pharmacol Physiol. 2023;50(1):39–49. doi: https://doi.org/10.1111/1440-1681.13722; Vaksmann G, Klug D. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2018;41(10):1378–1380. doi: https://doi.org/10.1111/pace.13446; Kohli U, Aziz Z, Beaser AD, Nayak HM. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2019;42(8):1146–1154. doi: https://doi.org/10.1111/pace.13668; Roston TM, Hart A, Krahn AD, Sanatani S. The challenge of implantable cardioverter-defibrillator programming and shock interpretation in treatment-refractory catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Med (Hagerstown). 2019;20(8):569–571. doi: https://doi.org/10.2459/JCM.0000000000000814; Miyake CY, Webster G, Czosek RJ, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: Success depends on substrate. Circ Arrhythm Electrophysiol. 2013;6(3):579–587. doi: https://doi.org/10.1161/CIRCEP.113.000170; Eckert H, El-Battrawy I, Veith M, et al. Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Pers Med. 2022;12(4):536. doi: https://doi.org/10.3390/jpm12040536.; Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(12):1319–1321. doi: https://doi.org/10.1111/j.1540-8167.2008.01211.x; Itoh H, Murayama T, Kurebayashi N, et al. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation. J Electrocardiol. 2021;69:111-118. doi: https://doi.org/10.1016/j.jelectrocard.2021.09.015; Richardson E, Spinks C, Davis A, et al. Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood. J Genet Couns. 2018;27(3):549-557. doi: https://doi.org/10.1007/s10897-017-0152-1; Roses-Noguer F, Jarman JWE, Clague JR, Till J. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2014;11(1):58-66. doi: https://doi.org/10.1016/j.hrthm.2013.10.027; Roston TM, Jones K, Hawkins NM, et al. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. Heart Rhythm. 2018;15(12):1791-1799. doi: https://doi.org/10.1016/j.hrthm.2018.06.046; Van Der Werf C, Lieve KV, Bos JM, et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J. 2019;40(35):2953-2961. doi: https://doi.org/10.1093/eurheartj/ehz309; Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm. 2006;3(12):1486-1489.; Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2011;8(6):864-871. doi: https://doi.org/10.1016/j.hrthm.2011.01.048; De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. Circulation. 2015;131(25):2185-2193. doi: https://doi.org/10.1161/CIRCULATIONAHA.115.015731; Schwartz PJ, Snebold NG, Brown AM. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. Am J Cardiol. 1976;37(7):1034-1040. doi: https://doi.org/10.1016/0002-9149(76)90420-3; Yagishita D, Chui RW, Yamakawa K, et al. Sympathetic nerve stimulation, not circulating norepinephrine, modulates T-peak to T-end interval by increasing global dispersion of repolarization. Circ Arrhythm Electrophysiol. 2015;8(1):174-185. doi: https://doi.org/10.1161/CIRCEP.114.002195; Jonesco T. Traitement chirurgical de l'angine de poitrine par la resection dusympathique cervico-thoracique. Presse Med. 1921;20:30.; Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med. 1971;285(16):903-904. doi: https://doi.org/10.1056/NEJM197110142851607; Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975;89(3):378-390. doi: https://doi.org/10.1016/0002-8703(75)90089-7; Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J. 1975;89(1): 45-50. doi: https://doi.org/10.1016/0002-8703(75)90008-3; Wilde AAM, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358(19):2024-2029. doi: https://doi.org/10.1056/NEJMoa0708006; Atallah J, Fynn-Thompson F, Cecchin F, et al. Video-Assisted Thoracoscopic Cardiac Denervation: A Potential Novel Therapeutic Option for Children With Intractable Ventricular Arrhythmias. Ann Thorac Surg. 2008;86(5):1620-1625. doi: https://doi.org/10.1016/j.athoracsur.2008.07.006; Schwartz PJ, Ackerman MJ. Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. Eur Heart J. 2022;43(22):2096-2102. doi: https://doi.org/10.1093/eurheartj/ehac134; Cho Y. Left cardiac sympathetic denervation: An important treatment option for patients with hereditary ventricular arrhythmias. J Arrhythm. 2016;32(5):340-343. doi: https://doi.org/10.1016/j.joa.2015.08.002; Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation. 1991;84(2):503-511. doi: https://doi.org/10.1161/01.cir.84.2.503; Li C, Hu D, Shang L, et al. Surgical left cardiac sympathetic denervation for long QT syndrome: effects on QT interval and heart rate. Heart Vessels. 2005;20(4):137-141. doi: https://doi.org/10.1007/s00380-005-0820-1; Waddell-Smith KE, Ertresvaag KN, Li J, et al. Physical and Psychological Consequences of Left Cardiac Sympathetic Denervation in Long-QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Arrhythm Electrophysiol. 2015;8(5): 1151-1158. doi: https://doi.org/10.1161/CIRCEP.115.003159; Dusi V, De Ferrari GM, Pugliese L, Schwartz PJ. Cardiac Sympathetic Denervation in Channelopathies. Front Cardiovasc Med. 2019;6:27. doi: https://doi.org/10.3389/fcvm.2019.00027; Perez PR, Hylind RJ, Roston TM, et al. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2023;32(7):790-797. doi: https://doi.org/10.1016/j.hlc.2023.01.018; https://vsp.spr-journal.ru/jour/article/view/3449

الاتاحة: https://vsp.spr-journal.ru/jour/article/view/3449
https://doi.org/10.15690/vsp.v23i2.2740

المؤلفون: I. V. Leontyeva, И. В. Леонтьева

المصدر: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 69, № 3 (2024); 6-18 ; Российский вестник перинатологии и педиатрии; Том 69, № 3 (2024); 6-18 ; 2500-2228 ; 1027-4065

مصطلحات موضوعية: кардиовертер-дефибриллятор, hypertrophic cardiomyopathy, sudden death, risk factors for sudden cardiac death, cardioverter-defibrillator, гипертрофическая кардиомиопатия, внезапная смерть, факторы риска внезапной сердечной смерти

وصف الملف: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/1997/1489; Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P. еt al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35(39): 2733–2779. DOI:10.1093/eurheartj/ehu284; Ommen S.R., Mital S., Burke M.A., Day S.M., Deswal A., Elliott P. et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020; 76: e159–e240. DOI:10.1016/j.jacc.020.08.045; Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., Barriales-Villa R., Basso C. et al. ESC Scientific Document Group2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44(37): 3503–3626. DOI:10.1093/eurheartj/ehad194; Maron B., Rowin E., Casey S., Lesser J., Garberich R., McGriff D.M. et al. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation 2016; 133(1): 62–73. DOI:10.1161/CIRCULATIONAHA.115.017633; Norrish G., Field E., Mcleod K., Ilina M., Stuart G., Bhole V. et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J 2019; 40: 986–993. DOI:10.1093/eurheartj/ehy798.; Marston N. A., Han L., Olivotto I., Day S. M., Ashley E. A., Michels M. et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J 2021; 42: 1988–1996. DOI:10.1093/eurheartj/ehab14; Kaski J. P., Kammeraad J. A. E., Blom N. A., Happonen J. M., Janousek J., Klaassen S. et al. Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy: A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology. Cardiol Young 2023; 33(5): 681–698. DOI:10.1017/S1047951123000872; Norrish G., Cleary A., Field E., Cervi E., Boleti O., Ziółkowska L. et al. Clinical features and natural history of pread olescent non-syndromic hypertrophic cardiomyopathy. J Am CollCardiol 2022; 79: 1986–1997. DOI:10.1016/j.jacc.2022.03.347; Norrish G., Cantarutti N., Pissaridou E., Ridout D, Limongell G., Elliott P. et al. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. Eur J Prev Cardiol 2017; 24(11): 1220–1230. DOI:10.1177/2047487317702519; Ostman-Smith I., Wettrell G., Keeton B., Holmgren D, Ergander U., Gould S. et al. Age-and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J 2008; 29(9): 1160–1167. DOI:10.1093/eurheartj/ehn122; Miron A., Lafreniere-Roula M., Steve Fan C. P., Armstrong K. R., Dragulescu A., Papaz T. et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020; 142: 217–229. DOI:10.1161/CIRCULATIONAHA.120.047235; Norrish G., Ding T., Field E., Ziólkowska L., Olivotto I., Limongelli G. et al. Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM risk-kids). JAMA Cardiol 2019; 4: 918–927. DOI:10.1001/jamacardio.2019.2861; Maurizi N., Passantino S., Spaziani G., Girolami F., Arretini A., Targetti M. et al. Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors forlethal arrhythmic events. JAMA Cardiol 2018; 3: 520–525. DOI:10.1001/jamacardio.2018.0789; Pettersen M.D., Du W., Skeens M.E., Humes, R.A. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 2008; 21(8): 922–934. DOI:10.1016/j.echo.2008.02.006; Lopez L., Frommelt P.C., Colan S.D., Trachtenberg F.L., Gongwer R., Stylianou M. et al. Pediatric Heart Network Echocardiographic Z Scores: Comparison with Other Published Models. J Am Soc Echocardiogr 2021; 34(2): 185–192. DOI:10.1016/j.echo.2020.09.019; Norrish G., Ding T., Field E., Cervi E., Ziółkowska L., Olivotto I. et al. Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol 2022; 15(5): e010075. DOI:10.1161/CIRCEP.121.010075; Ziolkowska L., Turska-Kmiec A., Petryka J., Kawalec W. Predictors of long-term outcome in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2016; 37: 448–458. DOI:10.1007/s00246–015–1298-y; Balaji S., DiLorenzo M.P., Fish F.A., Etheridge S.P., Aziz P.F., Russell M.W. et al. Risk factors for lethal arrhythmicvents in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study. Heart Rhythm 2019; 16: 1462–1467. DOI:10.1016/j.hrthm.2019.04.040; Ostman-Smith I., Sjoberg G., Rydberg A., Larsson P., Fernlund E. Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score. Open Heart 2017; 4(2): e000658. Published 2017 Oct 21. DOI:10.1136/openhrt-2017–000658; Monserrat L., Elliott P.M., Gimeno J.R., Sharma S., PenasLado M., McKenna W.J. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42(5): 873–879. DOI:10.1016/s0735-1097(03)00827-1; Norrish G., Chubb H., Field E., McLeod K., Ilina M., Spentzou G. et al. Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study. Europace 2021; 23(3): 400–408. DOI:10.1093/europace/euaa307; Fancia P., Santini D., Musumeci B., Semprini L., Adduci C., Pagannone E. et al. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2014; 25(11): 1180–1187. DOI:10.1111/jce.12492; Wang W., Lian Z., Rowin E.J., Maron B.J., Maron M.S., Link M.S. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol 2017; 10(3): e004604. DOI:10.1161/CIRCEP.116.004604; Yang W.I., Shim C.Y., Kim Y.J., Kim S.A., Rhee S.J., Choi E.Y. et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009; 22(12): 1338–1343. DOI:10.1016/j.echo.2009.09.016; Maskatia S.A., Decker J.A., Spinner J.A., Kim J.J., Price J.F., Jefferies J.L. et al. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2012; 33: 141–149. DOI:10.1007/ s00246-011-0106-6; Nguyen M.B., Venet M., Fan C.S., Dragulescu A., Rusin C.G., Mertens L.L. et al. Modeling the Relationship Between Diastolic Phenotype and Outcomes in Pediatric Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr 2023: S0894-7317(23)00653-3. Online ahead of print DOI:10.1016/j.echo.2023.11.025; Topriceanu C.C., Field E., Boleti O., Cervi E., Kaski J.P., Norrish G. Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy. Int J Cardiol 2023; 371: 523–525. DOI:10.1016/j.ijcard.2022.09.044; Assaad I., Gauvreau K., Rizwan R., Margossian R., Colan S., Chen M.H. Value of Exercise Stress Echocardiography in Children with Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr 2020; 33(7): 888–894.e2. DOI:10.1016/j.echo.2020.01.020; Xia K., Sun D., Wang R., Zhang Y. Factors associated with the risk of cardiac death in children with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart Lung 2022; 52: 26–36. DOI:10.1016/j.hrtlng.2021.11.006; Östman-Smith I., Sjöberg G., Alenius Dahlqvist J., Larsson P., Fernlund E. Sudden cardiac death in childhood hypertrophic cardiomyopathy is best predicted by a combination of electrocardiogram risk-score and HCMRisk-Kids score. Acta Paediatr 2021; 110(11): 3105–3115. DOI:10.1111/apa.16045; Bonura E.D., Bos J.M., Abdelsalam M.A., Araoz P.A., Ommen S.R., Ackerman M.J. et al. Cardiac Magnetic Resonance Imaging Features in Hypertrophic Cardiomyopathy Diagnosed at; Ali L.A., Marrone C., Martins D.S., Khraiche D., Festa P., Martini N. et al. Prognostic factors in hypertrophic cardiomyopathy in children: An MRI based study. Int J Cardiol 2022; 364: 141–147. DOI:10.1016/j.ijcard.2022.06.043; Petryka-Mazurkiewicz J., Ziolkowska L., Kowalczyk-Domagala M., Mazurkiewicz L., Boruc A., Spiewak M. et al. LGE for Risk Stratification in Primary Prevention in Children With HCM. JACC Cardiovasc Imag. 2020; 13(12): 2684–2686. DOI:10.1016/j.jcmg.2020.06.009; Sedaghat-Hamedani F., Kayvanpour E., Tugrul O.F., Lai A., Amr A., Haas J. et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol 2018; 107(1): 30–41. DOI:10.1007/s00392-017-1155-5; Norrish G., Ding T., Field E., McLeod K., Ilina M., Stuart G. et al. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. Europace 2019; 21(10): 1559–1565. DOI:10.1093/europace/euz118; Norrish G., Qu C., Field E., Cervi E., Khraiche D., Klaassen S. et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol 2022; 29(4): 678–686. DOI:10.1093/eurjpc/zwab181; Norrish G., Protonotarios A., Stec M., Boleti O., Field E., Cervi E. Performance of the PRIMaCY sudden death risk prediction model for childhood hypertrophic cardiomyopathy: implications for implantable cardioverter-defibrillator decision-making. Europace 2023; 25(11): euad330. DOI:10.1093/europace/euad330; Kamp A.N., Von Bergen N.H., Henrikson C.A., Makhoul M., Saarel E.V., Lapage M.J. et al. Implanted defibrillatorsin young hypertrophic cardiomyopathy patients: a multicenter study. Pediatr Cardiol 2013; 34: 1620–1627. DOI:10.1007/s00246-013-0676-6; Krause U., Müller M.J., Wilberg Y., Pietzka M., Backhoff D., Ruschewski W. et al. Transvenous and non-transvenous implantable cardioverter-defibrillators in children, adolescents, and adults with congenital heart disease: who is at risk for appropriate and inappropriate shocks? Europace 2019; 21(1): 106–113. DOI:10.1093/europace/euy219; https://www.ped-perinatology.ru/jour/article/view/1997

الاتاحة: https://www.ped-perinatology.ru/jour/article/view/1997
https://doi.org/10.21508/1027-4065-2024-69-3-6-18

المؤلفون: V. K. Lebedeva, O. E. Levinova, В. К. Лебедева, О. Э. Левинова

المصدر: The Siberian Journal of Clinical and Experimental Medicine; Том 38, № 4 (2023); 106-115 ; Сибирский журнал клинической и экспериментальной медицины; Том 38, № 4 (2023); 106-115 ; 2713-265X ; 2713-2927

مصطلحات موضوعية: необоснованный шок, implantable cardioverter-defibrillator, electrotherapy, inappropriate shock, имплантируемый кардиовертер-дефибриллятор, электротерапия

وصف الملف: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/2059/895; Barisone M., Hayter M., Ghirotto L., Catania G., Zanini M., Dal Molin A. et al. The experience of patients with an implantable cardioverter-defibrillator: a systematic review and meta-synthesis of qualitative studies. Eur. J. Cardiovasc. Nurs. 2022;21(7):677–686. DOI:10.1093/eurjcn/zvab135.; Fleeman B.E. Aleong R.G. Optimal strategies to reduce inappropriate implantable cardioverter-defibrillator shocks. Innov. Card. Rhythm. Manag. 2019;10(4):3623–3632. DOI:10.19102/icrm.2019.100403.; Stiles M.K., Fauchier L., Morillo C.A., Wilkoff B.L. 2019 HRS/EHRA/ APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2020;17(1):220–228. DOI:10.1016/j.hrthm.2019.02.03.; Joung B. Lexcen D., Ching C., Silver M., Piccini J., Sterns L. et al. Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks. Heart Rhythm. 2020;17(1):98–105. DOI:10.1016/j.hrthm.2019.07.027.; Tan V., Wilton S., Kuriachan V., Sumner G., Exner D. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ. Arrhythm. Electrophysiol. 2014; 7(1):164–70. DOI:10.1161/CIRCEP.113.001217.; Iannaccone M., Nombela-Franco L., Gallone G., Annone U., Di Marco A., Giannini F. et al. Impact of successful chronic coronary total occlusion recanalization on recurrence of ventricular arrhythmias in implantable cardioverter-defibrillator recipients for ischemic cardiomyopathy (VACTO PCI Study). Cardiovasc. Revasc. Med. 2022;43:104–111. DOI:10.1016/j.carrev.2022.03.029.; Barsheshet A., Goldenberg I., Moss A., Huang D., Zareba W., McNITT S. Effect of elapsed time from coronary revascularization to implantation of a Cardioverter defibrillator on long-term survival in the MADIT-II trial. J. Cardiovasc. Electrophysiol. 2011;22(11):1237–1242. DOI:10.1111/j.1540-8167.2011.02096.; Ursaru A.M., Petris A., Costache I. Comparable efficacy in ischemic and non-ischemic ICD recipients for the primary prevention of sudden cardiac death. Biomedicines. 2021;9(11):1595. DOI:10.3390/biomedicines9111595.; Илов Н.Н., Пальникова О.В., Стомпель Д.Р., Нечепуренко А.А. Клинические предикторы возникновения желудочковых тахиаритмий у больных со сниженной систолической функцией левого желудочка. Результаты одноцентрового проспективного исследования. Кардиология. 2021;61(5):32–40. DOI:10.18087/cardio.2021.5.n1480.; Лебедева В.К., Любимцева Т.А., Лебедев Д.С. Анализ электротерапии кардиовертерами-дефибрилляторами, имплантируемыми с целью первичной профилактики внезапной сердечной смерти. Российский кардиологический журнал. 2019;(7):26–32. DOI:10.15829/1560-4071-2019-7-26-32.; Чугунов И.А., Мареев Ю.В., Фудим М., Миронова Н.А., Мареев В.Ю., Давтян К.В. Модуляция сердечной сократимости в лечении пациентов с сердечной недостаточностью со сниженной фракцией выброса левого желудочка. Кардиология. 2022: 62(11):71–78. DOI:10.18087/cardio.2022.11.n2014.; Oosterwerff E., Adiyaman A., Elvan A., Ghani A., Hoek L., Breeman K. et al. Significantly less inappropriate shocks in ischemic patients compared to non-ischemic patients: The S-ICD experience of a high volume single-center. Pacing Clin. Electrophysiol. 2021;44(11):1918–1924. DOI:10.1111/pace.14364.; Moradi M., Shahabi J., Vakhshoori M., Shafie D. Associated factors with the occurrence of inappropriate shocks among admitted patients with ischemic cardiomyopathy. ARYA Atheroscler. 2022;18(10):1–7. DOI:10.48305/arya.2022.11742.2372.; Defaye P., Boveda S., Klug D., Beganton F., Piot O., Narayanan K. et al. Dualvs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Defibrillateur Automatique Implantable-Prevention Primaire registry. Europace. 2017;19(9):1478– 1484. DOI:10.1093/europace/euw230.; Peterson P.N., Greenlee R.T., Go A.S. Comparison of inappropriate shocks and other health outcomes between singleand dual-chamber implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: results from the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators. J. Am. Heart Assoc. 2017;6(11):e006937. DOI:10.1161/JAHA.117.006937.; Burger A.L., Schmidinger H., Ristl R., Pezawas T. Appropriate and inappropriate therapy in patients with singleor multi-chamber implantable cardioverter-defibrillators. Hellenic J. Cardiol. 2020;61(6):421–427. DOI:10.1016/j.hjc.2020.03.001.; https://www.sibjcem.ru/jour/article/view/2059

الاتاحة: https://www.sibjcem.ru/jour/article/view/2059
https://doi.org/10.29001/2073-8552-2023-38-4-106-115

المؤلفون: А.В. Верещагина, Т.М. Ускач, О.В. Сапельников, В.А. Аманатова, И.Р. Гришин

المصدر: Патология кровообращения и кардиохирургия, Vol 27, Iss 1, Pp 17-29 (2023)

مصطلحات موضوعية: внезапная сердечная смерть, кардиовертер-дефибриллятор, первичная профилактика, хроническая сердечная недостаточность, Surgery, RD1-811

وصف الملف: electronic resource

Relation: https://journalmeshalkin.ru/index.php/heartjournal/article/view/1175; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

URL الوصول: https://doaj.org/article/aaf97414ae1442e89b5d49cd29be97e0

المؤلفون: O. S. Kobyakova, I. A. Deev, D. S. Tyufilin, G. O. Alexandrov, E. S. Kulikov

المصدر: Бюллетень сибирской медицины, Vol 21, Iss 1, Pp 109-120 (2022)

مصطلحات موضوعية: хниз, удаленный мониторинг, ум, телемедицина, бронхиальная астма, хобл, имплантируемый кардиовертер-дефибриллятор, икд, имплантируемый петлевой регистратор, имплантируемые кардиостимуляторы, сахарный диабет, телемониторинг, Medicine

وصف الملف: electronic resource

Relation: https://bulletin.ssmu.ru/jour/article/view/4706; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684

URL الوصول: https://doaj.org/article/f9a2e6ec0a604f9e98972cc7335611ae

المؤلفون: A. Yu. Amiraslanov, E. V. Dedukh, E. A. Artyukhina, А. Ю. Амирасланов, Е. В. Дедух, Е. А. Артюхина

المصدر: The Siberian Journal of Clinical and Experimental Medicine; Том 38, № 2 (2023); 235-240 ; Сибирский журнал клинической и экспериментальной медицины; Том 38, № 2 (2023); 235-240 ; 2713-265X ; 2713-2927

مصطلحات موضوعية: фибрилляция предсердий, implantable cardioverter-defibrillator, ventricular tachycardia, atrial fibrillation, имплантируемый кардиовертер-дефибриллятор, желудочковая тахикардия

وصف الملف: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/1809/831; Van Dijk V.F., Boersma L.V. The subcutaneous implantable cardioverter defibrillator in 2019 and beyond. Trends Cardiovasc. Med. 2020;30(6):378–384. DOI:10.1016/j.tcm.2019.09.006.; Glikson M., Nielsen C., Kronborg M., Michowitz Y., Auricchio A., Barbash I.M. et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur. Heart J. 2021;42(35):3427–3520. DOI:10.1093/eurheartj/ehab364.; Лебедева В.К., Любимцева Т.А., Лебедев Д.С. Удаленный мониторинг в наблюдении за пациентами с электрокардиостимуляторами, имплантируемыми кардиовертерами-дефибрилляторами и устройствами сердечной ресинхронизирующей терапии. Вестник аритмологии. 2017;(88):57–61.; Burri H., Senouf D. Remote monitoring and follow-up of pacemakers and implantable cardioverter defibrillators. Europace. 2009;11(6):701–709. DOI:10.1093/europace/eup110.; Health Quality Ontario. Remote Monitoring of Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy and Permanent Pacemakers: A Health Technology Assessment. Ont. Health Technol.Assess Ser. 2018;18(7):1–199.; Lazarus A. Remote, wireless, ambulatory monitoring of implantable pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy systems: analysis of a worldwide database. Pacing Clin. Electrophysiol. 2007;30(s1):S2–S12. DOI:10.1111/j.1540-8159.2007.00595.x.; Spencker S., Coban N., Koch L., Schirdewan A., Müller D. et al. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure. Europace. 2009;11(4):483–488. DOI:10.1093/europace/eun350.; Varma N., Epstein A.E., Irimpen A., Schweikert R., Love C. et al. TRUST Investigators. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation. 2010;122(4):325–332. DOI:10.1161/CIRCULATIONAHA.110.937409.; Mabo P., Victor F., Bazin P., Ahres S., Babuty D., Da Costa A. et al. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). Eur. Heart J. 2012;33(9):1105–1111. DOI:10.1093/eurheartj/ehr419.; Costa R., Silva K.R.D., Saucedo S.C.M., Silva L.A., Crevelari E.S., Nascimento W.T.J. et al. Impact of the COVID-19 Pandemic on сardiac implantable electronic devices procedures in a Tertiary Referral Center. Arq. Bras. Cardiol. 2021;117(4):765–769. DOI:10.36660/abc.20201378.; Maines M., Zorzi A., Benetollo P.P., Guarrera G.M., Moz M., Manica A. et al. Short-term outcome associated with remote evaluation (telecardiology) of patients with cardiovascular diseases during the COVID-19 pandemic. Int. J. Cardiol. Heart Vasc. 2020;30:100625. DOI:10.1016/j.ijcha.2020.100625.; Трунова О.С., Дурманов С.С., Базылев В.В. Влияние удаленного мониторинга работы имплантируемого кардиовертера-дефибриллятора на качество жизни пациентов. Вестник аритмологии.2019;26(1):17–23. DOI:10.25760/VA-2019-95-17-23.; Дамрина Е.В., Илов Н.Н. Амбулаторное ведение больных с ИКД: тестирование в клинике или удаленный мониторинг? Сибирский журнал клинической и экспериментальной медицины. 2017;32(1):84–87.DOI:10.29001/2073-8552-2017-32-1-84-87.; Ricci R., Morichelli L., Santini M. Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation. Europace. 2009;11(1):54–61. DOI:10.1093/europace/eun303.; Zaman J.A.B., Chua K., Sovari A.A., Gunderson B., Gang E.S., Ploux S.et al. Early diagnosis of defibrillation lead dislodgement. JACC Clin. Electrophysiol. 2018;4(8):1075–1088. DOI:10.1016/j.jacep.2018.03.015.; https://www.sibjcem.ru/jour/article/view/1809

الاتاحة: https://www.sibjcem.ru/jour/article/view/1809
https://doi.org/10.29001/2073-8552-2023-38-2-235-240

المؤلفون: Moscalu, V.D., Răcilă, V.Ş., Rizov, M., Guțan, I., Vataman, E.B.

المصدر: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 72 (1) 82-90

مصطلحات موضوعية: insuficienţă cardiacă, defibrilator cardiac implantabil, terapie de resincronizare cardiacă, cardioversie electrică, ablație, revascularizarea miocardului, suport circulator mecanic, transplant cardiac, heart failure, implantable heart defibrillator, cardiac resynchronization therapy, electrical cardioversion, ablation, myocardial revascularization, mechanical circulatory support, heart transplant, сердечная недостаточность, имплантируемый дефибриллятор сердца, сердечная ресинхронизирующая терапия, электрическая кардиоверсия, абляция, реваскуляризация миокарда, механическая поддержка кровообращения, трансплантация сердца

وصف الملف: application/pdf

Relation: info:eu-repo/grantAgreement/EC/FP7/17185/EU/Alternative terapeutice noi de ameliorere a prognozei de lungă durată a pacienților cu insuficiență cardiacă cronică prin implementarea strategiilor chirurgicale, intervenționale și de recuperare peri/20.80009.8007.34; https://ibn.idsi.md/vizualizare_articol/153777; urn:issn:18570011

الاتاحة: https://ibn.idsi.md/vizualizare_articol/153777
https://doi.org/10.52692/1857-0011.2022.1-72.13

المؤلفون: Lipchak, D. A., Chupov, A. A.

المصدر: URAL RADIO ENGINEERING JOURNAL; Том 5, № 4 (2021): URAL RADIO ENGINEERING JOURNAL ; 2588-0462 ; 2588-0454

مصطلحات موضوعية: arrhythmia, digital signal processing, filtering, machine learning, automatic external defibrillator, defibrillation, аритмия, цифровая обработка сигнала, фильтрация, машинное обучение, автоматический наружный дефибриллятор, дефибрилляция

وصف الملف: application/pdf

Relation: https://journals.urfu.ru/index.php/urj/article/view/5730/pdf; https://journals.urfu.ru/index.php/urj/article/view/5730

الاتاحة: https://journals.urfu.ru/index.php/urj/article/view/5730

المؤلفون: L. Sokolova A., I. Gorlova A., M. Omelchenko Yu., B. Bondarenko B., Л. Соколова А., И. Горлова А., М. Омельченко Ю., Б. Бондаренко Б.

المصدر: Translational Medicine; Том 9, № 1 (2022); 5-11 ; Трансляционная медицина; Том 9, № 1 (2022); 5-11 ; 2410-5155 ; 2311-4495

مصطلحات موضوعية: cardiopulmonary resuscitation, commotio cordis, defibrillator, preventive measure, sudden death in young athletes, ventricular fibrillation, внезапная смерть у молодых спортсменов, дефибриллятор, профилактика, сердечно-легочная реанимация, фибрилляция желудочков

وصف الملف: application/pdf

Relation: https://transmed.almazovcentre.ru/jour/article/view/665/453; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1370; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1371; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1372; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1373; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1374; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1375; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1376; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1377; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1378; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1379; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/665/1380; Maron BJ, Estes NA 3rd. Commotio cordis. N Engl J Med. 2010; 362(10):917-27. DOI:10.1056/NEJMra0910111.; Kelli M. Death touch: science behind the legend of Dim-Mak. Boulder, CO: Paladin Press, 2001. P. 184.; Maron BJ, Poliac LC, Kaplan JA, et al. Blunt impact to the chest leading to sudden death from cardiac arrest during sports activities. N Engl J Med. 1995; 333(6):337–342. DOI:10.1056/NEJM199508103330602.; Maron BJ, Gohman TE, Kyle SB, et al. Clinical profile and spectrum of commotio cordis. JAMA. 2002; 287(9):1142–1146. DOI:10.1001/jama.287.9.1142.; Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 2009; 119(8):1085–1092. DOI:10.1161/CIRCULATIONAHA.108.804617.; Maron BJ, Ahluwalia A, Haas TS, et al. Global epidemiology and demographics of commotio cordis. Heart Rhythm. 2011; 8(12):1969–1971. DOI:10.1016/j.hrthm.2011.07.014.; Harmon KG, Drezner JA, Maleszewski JJ, et al. Pathogeneses of sudden cardiac death in national collegiate athletic association athletes. Circ Arrhythm Electrophysiol. 2014; 7(2):198–204. DOI:10.1161/CIRCEP.113.001376.; Колкин Я.Г., Ватутин Н.Т., Момот Н.В. и др. «Contusio» и «commotio» сердца. Подобия и отличия. Архив клинической и экспериментальной медицины. 2020; 29(3):300–308.; Jones LA, Sullivan RW. Ventricular Tachycardia: A Rare Commotio Cordis Presentation. Pediatr Emerg Care. 2017; 33(2):109–111. DOI:10.1097/PEC.0000000000000685.; Maron BJ, Haas TS, Ahluwalia A, et al. Increasing survival rate from commotio cordis. Heart Rhythm. 2013; 10(2):219–223. DOI:10.1016/j.hrthm.2012.10.034.; Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation. 2006; 114(15):1633–1644. DOI:10.1161/CIRCULATIONAHA.106.613562.; Schlomka G. Expertise on a case of commotio cordis. Dtsch. Gesundheitsw. 1953; 8(1):11–12. In German [Schlomka G. Begutachtung eines Falles von Commotio cordis [Expertise on a case of commotio cordis]. Dtsch Gesund-heitsw. 1953 Jan 1;8(1):11–12].; Link MS. Commotio cordis: ventricular fibrillation triggered by chest impact-induced abnormalities in repolarization. Circ Arrhythm Electrophysiol. 2012; 5(2):425–432. DOI:10.1161/CIRCEP.111.962712.; Madias C, Maron BJ, Weinstock J, et al. Commotio cordis--sudden cardiac death with chest wall impact. J Cardiovasc Electrophysiol. 2007; 18(1):115–122. DOI:10.1111/j.1540-8167.2006.00684.x.; Guthrie K. Case of Commotio Cordis. Life in the Fast Lane (LITFL) Library, 2019.; Link MS, Maron BJ, Wang PJ, et al. Upper and lower limits of vulnerability to sudden arrhythmic death with chest-wall impact (commotio cordis). J Am Coll Cardiol. 2003; 41(1):99–104. DOI:10.1016/s0735-1097(02)02669-4.; Kalin J, Madias C, Alsheikh-Ali AA, et al. Reduced diameter spheres increases the risk of chest blow-induced ventricular fibrillation (commotio cordis). Heart Rhythm. 2011; 8(10):1578–1581. DOI:10.1016/j.hrthm.2011.05.009.; Макаров Л.М. Спорт и внезапная смерть детей. Российский вестник перинатологии и педиатрии. 2017; 62(1):40–46. DOI:10.21508/1027-4065-2017-62-1-40-46.; Kohl P, Nesbitt AD, Cooper PJ, Lei M. Sudden cardiac death by Commotio cordis: role of mechanoelectric feedback. Cardiovasc Res. 2001; 50(2):280–289. DOI:10.1016/s0008-6363(01)00194-8.; Bode F, Franz MR, Wilke I, et al. Ventricular fibrillation induced by stretch pulse: implications for sudden death due to commotio cordis. J Cardiovasc Electrophysiol. 2006; 17(9):1011–1017. DOI:10.1111/j.1540-8167.2006.00547.x.; Madias C, Maron BJ, Supron S, et al. Cell membrane stretch and chest blow-induced ventricular fibrillation: commotio cordis. J Cardiovasc Electrophys-iol. 2008; 19(12):1304–1309. DOI:10.1111/j.1540-8167.2008.01267.x.; Link MS, Maron BJ, Wang PJ, et al. Reduced risk of sudden death from chest wall blows (commotio cordis) with safety baseballs. Pediatrics. 2002; 109(5):873–877. DOI:10.1542/peds.109.5.873.; Lupariello F, Di Vella G. The role of the autopsy in the diagnosis of commotio cordis lethal cases: Review of the literature. Leg Med (Tokyo). 2019; 38:73–76. DOI:10.1016/j.legalmed.2019.04.007.; Geddes LA, Roeder RA. Evolution of our knowledge of sudden death due to commotio cordis. Am J Emerg Med. 2005; 23(1):67–75. DOI:10.1016/j.ajem.2003.12.023.; Maron BJ, Haas TS, Ahluwalia A, et al. Increasing survival rate from commotio cordis. Heart Rhythm. 2013; 10(2):219–23. DOI:10.1016/j.hrthm.2012.10.034.; Link MS, Estes NAM 3rd, Maron BJ. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13: Commotio Cordis: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015; 66(21):2439–2443. DOI:10.1016/j.jacc.2015.09.045.; https://transmed.almazovcentre.ru/jour/article/view/665

الاتاحة: https://transmed.almazovcentre.ru/jour/article/view/665
https://doi.org/10.18705/2311-449-2022-9-1-5-11

المؤلفون: A. V. Vereshchagina, T. M. Uskach, O. V. Sapelnikov, V. A. Amanatova, I. R. Grishin, A. A. Kulikov, V. S. Kostin, R. S. Akchurin, А. В. Верещагина, Т. М. Ускач, О. В. Сапельников, В. A. Аманатова, И. Р. Гришин, А. А. Куликов, В. С. Костин, Р. С. Акчурин

المساهمون: The study was performed with the support of the National Medical Research Centre of Cardiology named after academician E.I. Chazov., Исследование проведено при поддержке Национального медицинского исследовательского центра кардиологии.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 18, No 4 (2022); 427-432 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 4 (2022); 427-432 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: подкожный имплантируемый кардиовертер-дефибриллятор, chronic heart failure with low ejection fraction, subcutaneous implantable cardioverter-defibrillator, хроническая сердечная недостаточность с низкой фракцией выброса

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2793/2342; Moss AJ, Hall WJ, Cannom DS, et. al. Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. New Engl J Med. 1996;335(26):1933-40. DOI:10.1056/nejm199612263352601.; Moss AJ, Zareba W, Hall WJ, et. al. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. New Engl J Med. 2002;346(12):877-83. DOI:10.1056/nejmoa013474.; Kong MH, Fonarow G C, Peterson ED, et. al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol. 2011;57(7):794-801. DOI:10.1016/j.jacc.2010.09.064.; Kaya E, Rassaf T, Wakili R. Subcutaneous ICD: Current standards and future perspective. Int J Cardiol Heart Vasc. 2019;24:100409. DOI:10.1016/j.ijcha.2019.100409.; Honarbakhsh S, Providencia R, Srinivasan N, et al. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. Int J Cardiol. 2017;228:280-5. DOI:10.1016/j.ijcard.2016.11.017.; Olde Nordkamp LO, Knops R, Bardy G, et. al. Rationale and design of the PRAETORIAN trial: a Prospective, Randomized comparison of subcutaneous and transvenous implantable cardioverterdefibrillator therapy. American heart journal. 2012;163(5):753-760. Doi:10.1016/j.ahj.2012.02.012.; Gold S MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator PostApproval Study: clinical characteristics and perioperative results. Heart Rhythm. 2017;10(14):1456-63. DOI:10.1016/j.hrthm.2017.05.016.; Kamp Nicholas J, Al-Khatib Sana M. The subcutaneous implantable cardioverter-defibrillator in review. Am Heart J. 2019;217:131-9. DOI:10.1016/j.ahj.2019.08.010.; Weiss R, Knight BP, Gold MR, et. al. Safety and efficacy of a totally subcutaneous implantablecardioverter defibrillator. Circulation. 2013;128(9):944-53. DOI:10.1161/CIRCULATIONAHA.113.003042.; Boersma L, Barr C, Knops R, et. al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol. 2017;70(7):842-4. DOI:10.1016/j.jacc.2017.06.040.; Knops RE, Olde Nordkamp LRA, Delnoy PPHM, et. al. Subcutaneous or Transvenous Defibrillator Therapy Collaborators. New Engl J Med. 2020;383:526-36. DOI:10.1056/NEJMoa1915932.; Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2018;72(2):91-220. DOI:10.1016/j.hrthm.2017.10.035.; Priori SG, Blomstrom-LundqvistC, Mazzanti A, et. al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867. DOI:10.1093/eurheartj/ehv316.; Лебедев Д.С., Михайлов Е.Н., Неминущий Н.М., и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский Кардиологический Журнал. 2021;26(7):4600. DOI:10.15829/1560-4071-2021-4600.; Larbig R, Bettin M, Motloch LJ, et al. Management of inappropriate shocks/T-wave-oversensing in S-ICD®-patients. Herzschr Elektrophys. 2018;29(1):122-6. DOI:10.1007/s00399-018-0555-1.; Rhythm Management Product Performance Report Q3 Edition 2021 [cited 2022 Jan 10]. Available from: https://www.bostonscientific.com/content/dam/bostonscientific/quality/ppr/2021/q3/Q3%202021%20CRM%20Product%20Performance%20Report%20Rev%20B.pdf.; Gold MR, Lambiase PD, El-Chami MF, et. al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021;143(1):7-17. DOI:10.1161/CIRCULATIONAHA.120.048728.; Moss AJ, Schuger C, Beck CA, et al., for the MADIT-RIT Trial, Investigators Reduction in Inappropriate Therapy and Mortality through ICD Programming. New England Journal of Medicine. 2012;367(24):2275-83. DOI:10.1056/NEJMoa1211107.; Lambiase P.D., Barr C., Theuns D.A., et. al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35(25):1657-65. DOI:10.1093/eurheartj/ehu112.; Burke MC, Gold MR, Knight BP, et. al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. Journal of the American College of Cardiology. 2015;65(16):1605-15. DOI:10.1016/j.jacc.2015.02.047.; Boersma L, Burke MC, Neuzil P, et. al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm. 2016;13(1):157-64. DOI:10.1016/j.hrthm.2015.08.039.; Knops RE, Brouwer TF, Barr CS et al. The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace. 2016;18(7):1010-5. DOI:10.1093/europace/euv299.; https://www.rpcardio.com/jour/article/view/2793

الاتاحة: https://www.rpcardio.com/jour/article/view/2793
https://doi.org/10.20996/1819-6446-2022-08-05

المؤلفون: T. Bessonova O., F. Gorkavenko V., D. Shchurov G., Yu. Seryapina V., O. Chetverikova R., V. Omelyanovskiy V., S. Krivolapov N., N. Neminushchiy M., A. Kalemberg A., Т. Бессонова О., Ф. Горкавенко В., Д. Щуров Г., Ю. Серяпина В., О. Четверикова Р., В. Омельяновский В., С. Криволапов Н., Н. Неминущий М., А. Калемберг А.

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 15, No 1 (2022); 5-22 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 15, No 1 (2022); 5-22 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: Implantable cardioverter-defibrillator, ICD, sudden cardiac death, cost-effectiveness analysis, budget impact analysis, имплантируемый кардиовертер-дефибриллятор, ИКД, внезапная сердечная смерть, клинико-экономический анализ, анализ влияния на бюджет

وصف الملف: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/655/411; https://www.pharmacoeconomics.ru/jour/article/downloadSuppFile/655/59; Росстат. Число умерших по причинам смерти в 2020 году. URL: https://rosstat.gov.ru (дата обращения 03.02.2022).; Клинически рекомендации. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_ZHNR.pdf (дата обращения 03.02.2022).; Фатенков О.В., Рубаненко О.А., Яшин С.С., Авезова Д.Б. Современные аспекты понятия, этиологии, патогенеза и профилактики внезапной сердечной смерти. Наука и инновации в медицине. 2017; 2: 20–5.; Филиппов Е.В., Якушин С.С. Внезапная сердечная смерть: проблема стратификации риска и выбора лекарственного препарата. Рациональная фармакотерапия в кардиологии. 2011; 7 (2): 212–8.; Ладеев А.Ю., Марочков А.В., Дмитриева В.Н. История создания и развития имплантируемых кардиовертеров-дефибрилляторов. Новости хирургии. 2016; 24 (4): 317–27.; Ардашев А.В., Желяков Е.Г. Применение имплантируемых кардиовертеров-дефибрилляторов для профилактики внезапной сердечной смерти. Oпыт главного военного клинического госпиталя им. Н.Н. Бурденко. Российский кардиологический журнал. 2004; 9 (3): 35–41.; Бокерия Л.А., Милиевская Е.Б., Кудзоева З.Ф. и др. Сердечнососудистая хирургия – 2018. Болезни и врожденные аномалии системы кровообращения. М.: НМИЦССХ им. А.Н. Бакулева МЗ РФ; 2019: 270 с.; Бокерия Л.А., Милиевская Е.Б., Прянишников В.В., Юрлов И.А. Сердечно-сосудистая хирургия – 2020. Болезни и врожденные аномалии системы кровообращения. Ежегодный статистический сборник. М.: НМИЦССХ им. А.Н. Бакулева МЗ РФ; 2021: 294 с.; Омельяновский В.В., Авксентьева М.В., Хачатрян Г.Р. и др. Методические рекомендации по использованию математического моделирования в клинико-экономических исследованиях и исследованиях с использованием анализа влияния на бюджет. М.: ФГБУ ЦЭККМП МЗ РФ; 2019: 59 с.; Тепцова Т.С., Мусина Н.З., Омельяновский В.В. Оценка референтного значения инкрементального показателя «затраты– эффективность» для российской системы здравоохранения. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (4): 367–76. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.071.; International Monetary Fund. Inflation rate, average consumer prices. 2022. URL: https://www.imf.org/external/datamapper/PCPIPCH@WEO/OEMDC/RUS (дата обращения 06.02.2022).; Goldenberg I., Gillespie J., Moss A.J., et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation. 2010; 122 (13): 1265–71. https://doi.org/10.1161/CIRCULATIONAHA.110.940148.; Connolly S.J., Hallstrom A.P., Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000; 21 (24): 2071–8. https://doi.org/10.1053/euhj.2000.2476.; A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997; 337 (22): 1576–84. https://doi.org/10.1056/NEJM199711273372202.; Kuck K.H., Cappato R., Siebels J., Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102 (7): 748–54. https://doi.org/10.1161/01.cir.102.7.748.; Connolly S.J., Gent M., Roberts R.S., et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000; 101 (11): 1297–302. https://doi.org/10.1161/01.cir.101.11.1297.; WebPlotDigitizer 4.5. URL: https://apps.automeris.io/wpd/ (дата обращения 05.12.2021).; Guyot P., Ades A.E., Ouwens M.J., Welton N.J. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12: 9. https://doi.org/10.1186/1471-2288-12-9.; RStudio Team. URL: https://www.rstudio.com/ (дата обращения 02.02.2022).; Jackson C.H. flexsurv: a platform for parametric survival modeling in R. J Stat Softw. 2016; 70: i08. https://doi.org/10.18637/jss.v070.i08.; Ranasinghe I., Parzynski C.S., Freeman J.V., et al. Long-term risk for device-related complications and reoperations after implantable cardioverter-defibrillator implantation: an observational cohort study. Ann Intern Med. 2016; 165 (1): 20–9. https://doi.org/10.7326/M15-2732.; Gidwani R., Russell L.B. Estimating transition probabilities from published evidence: a tutorial for decision modelers. Pharmacoeconomics. 2020; 38 (11): 1153–64. https://doi.org/10.1007/s40273-020-00937-z.; da Silva K.R., Costa R., Garcia Rodrigues C., et al. Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials. Eur J Cardiovasc Nurs. 2018; 17 (3): 196–206. https://doi.org/10.1177/1474515117739619.; Tomzik J., Koltermann K.C., Zabel M., et al. Quality of life in patients with an implantable cardioverter defibrillator: a systematic review. Front Cardiovasc Med. 2015; 2: 34. https://doi.org/10.3389/fcvm.2015.00034.; Cowie M.R., Marshall D., Drummond M., et al. Lifetime costeffectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009; 11 (6): 716–26. https://doi.org/10.1093/europace/eup068.; Smith T., Jordaens L., Theuns D.A., et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013; 34 (3): 211–9. https://doi.org/10.1093/eurheartj/ehs090.; Sanders G.D., Kong M.H., Al-Khatib S.M., Peterson E.D. Costeffectiveness of implantable cardioverter defibrillators in patients ≥65 years of age. Am Heart J. 2010; 160 (1): 122–31. https://doi.org/10.1016/j.ahj.2010.04.021.; Owens D.K., Sanders G.D., Heidenreich P.A., et al. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J. 2002; 144 (3): 440–8. https://doi.org/10.1067/mhj.2002.125501.; Постановление Правительства РФ от 28.12.2021 № 2505 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2022 год и на плановый период 2023 и 2024 годов». URL: https://base.garant.ru/403335795/ (дата обращения 18.02.2022).; Проект приказа Минздрава России «Об утверждении стандарта медицинской помощи взрослым при желудочковых нарушениях ритма» (по состоянию на 21.12.2020). URL: http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=PNPA&n=66310#uvKXB1Tucu 4VwBtu (дата обращения 18.02.2022).; KRASOFT. Информационно-аналитическая система «Закупки». URL: http://krasoft.ru/ (дата обращения 15.05.2021).; Письмо Минздрава России от 31.12.2020 № 11-7/И/2-20700 «О направлении разъяснений по вопросам формирования и экономического обоснования территориальных программ государственных гарантий бесплатного оказания гражданам медицинской помощи на 2021 год и на плановый период 2022 и 2023 годов. URL: https://docs.cntd.ru/document/573366545 (дата обращения 18.02.2022).; Шаваров А.А., Джанджгава А.О., Ардашев А.В. Нарушения функционирования электрокардиостимуляторов и кардиовертеров-дефибрилляторов. В кн.: Ардашев А.В. (ред.) Клиническая аритмология. М.: Медпрактика; 2009: 689–705.; Постановление Правительства РФ от 28.12.2020 № 2299 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2021 год и на плановый период 2022 и 2023 годов». URL: https://base.garant.ru/400165890/ (дата обращения 18.02.2022).; Серяпина Ю.В., Пустовалов Д.Н., Мусина Н.З. Потребность в имплантации кардиовертеров-дефибрилляторов в Российской Федерации. Медицинские технологии. Оценка и выбор. 2021; 1: 46–53. https://doi.org/10.17116/medtech20214301146.; Völler H., Kamke W., Klein H.U., et al. Clinical practice of defibrillator implantation after myocardial infarction: impact of implant time: results from the PreSCD II Registry. Europace. 2011; 13 (4): 499–508. https://doi.org/10.1093/europace/euq426.; https://www.pharmacoeconomics.ru/jour/article/view/655

الاتاحة: https://www.pharmacoeconomics.ru/jour/article/view/655
https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.130

المؤلفون: A. T. Teplyakov, N. I. Tarasov, L. K. Isakov, E. V. Grakova, M. N. Sinkova, K. V. Kopieva, О. B. Garmaeva, O. N. Ogurkova, V. V. Kalyuzhin, E. V. Kalyuzhina

المصدر: Бюллетень сибирской медицины, Vol 17, Iss 3, Pp 140-150 (2018)

مصطلحات موضوعية: хроническая сердечная недостаточность, имплантируемый кардиовертер-дефибриллятор, сердечно-сосудистые события, прогноз, биомаркеры, эндотелин-1, растворимая форма белка st2, Medicine

وصف الملف: electronic resource

Relation: https://bulletin.ssmu.ru/jour/article/view/1293; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684

URL الوصول: https://doaj.org/article/07e5463310614dc8a92c1f489d4c33d3

المؤلفون: G. A. Gromyko, S. M. Yashin, E. V. Lyan, A. I. Kazakov

المصدر: Вестник хирургии имени И.И. Грекова, Vol 172, Iss 2, Pp 020-024 (2018)

مصطلحات موضوعية: атетерная аблация, желудочковая тахикардия, имплантированный кардиовертер-дефибриллятор, catheter ablation, ventricular tachycardia, implanted cardioverter-defibrillator, Surgery, RD1-811

وصف الملف: electronic resource

Relation: https://www.vestnik-grekova.ru/jour/article/view/729; https://doaj.org/toc/0042-4625

URL الوصول: https://doaj.org/article/87678236ae124ceba1187f7e40088c87

المؤلفون: О. Сапельников, А. Куликов, Д. Черкашин, И. Гришин, О. Николаева, Д. Ардус, А. Ширяев, Р. Акчурин

المصدر: Патология кровообращения и кардиохирургия, Vol 23, Iss 4 (2019)

مصطلحات موضوعية: имплантируемый кардиовертер-дефибриллятор, имплантируемое устройство, электрокардиостимулятор, экстракция электродов, Surgery, RD1-811

وصف الملف: electronic resource

Relation: https://journalmeshalkin.ru/index.php/heartjournal/article/view/676; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

URL الوصول: https://doaj.org/article/79b124857f244a7cb3aa198fd2f96c0e

المؤلفون: И. Е. Доровских, Ю. В. Вахненко, В. В. Шабанов, Е. Н. Гордиенко, А. Н. Вереветинов

المصدر: Патология кровообращения и кардиохирургия, Vol 20, Iss 3, Pp 126-131 (2016)

مصطلحات موضوعية: кардиомиопатия, некомпактный миокард, кардиовертер-дефибриллятор, Surgery, RD1-811

وصف الملف: electronic resource

Relation: http://journalmeshalkin.ru/index.php/heartjournal/article/view/339; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

URL الوصول: https://doaj.org/article/b108df6e50324441948e7929228adffb

المؤلفون: T. G. Vaikhanskaya, L. N. Sivitskaya, N. G. Danilenko, T. V. Kurushka, O. G. Davydenko

المصدر: Евразийский Кардиологический Журнал, Vol 0, Iss 1, Pp 3-11 (2016)

مصطلحات موضوعية: белки ядерной ламины, мутации гена ламина а/с (lmna), дилатационная кардиомиопатия (дкмп), жизнеугрожающие аритмии, кардиовертер-дефибриллятор (квд), nuclear lamin proteins, lmna gene mutations, dilated cardiomyopathy (dcm), life-threatening arrhythmias, cardioverter-defibrillator, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.heartj.asia/jour/article/view/5657; https://doaj.org/toc/2225-1685; https://doaj.org/toc/2305-0748

URL الوصول: https://doaj.org/article/6921482a975c4b1f93220f85685384ac

المؤلفون: Larisa A. Balykova, Elena I. Naumenko, Nataljya V. Ivyanskaya, Yulia A. Petrushkina, Ekaterina A. Vlasova, Nadezhda N. Urzjaeva, Irina V. Leontieva, Anna N. Urzjaeva, Л. А. Балыкова, Е. И. Науменко, Н. В. Ивянская, Ю. А. Петрушкина, Е. А. Власова, Н. Н. Урзяева, И. В. Леонтьева, А. Н. Урзяева

المصدر: Current Pediatrics; Том 18, № 2 (2019); 125-133 ; Вопросы современной педиатрии; Том 18, № 2 (2019); 125-133 ; 1682-5535 ; 1682-5527

مصطلحات موضوعية: клиническое наблюдение, myocarditis, dilated cardiomyopathy, heart failure, heart transplantation, diagnostics, treatment, MCS, mechanical circulatory support, complications, cardioverter defibrillator, risk, clinical case, миокардит, дилатационная кардиомиопатия, сердечная недостаточность, трансплантация сердца, диагностика, лечение, механическая поддержка кровообращения, осложнения, кардиовертер-дефибриллятор, риск

وصف الملف: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/2078/861; Клинические рекомендации «Хроническая сердечная недостаточность у детей» (утв. Минздравом России) [интернет]. / Под ред. Баранова А.А., Намазовой-Барановой Л.С., Басаргиной Е.Н., и др. — М.: Союз педиатров России; Ассоциация детских кардиологов России; 2016. — 16 с. Доступно по: http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=326053&fld=134&dst=100001,0&rnd=0.24511092809802348#03927419651004245. Ссылка активна на 12.01.2019.; Das BB. Current state of pediatric heart failure. Children (Basel). 2018;5(7). pii: E88. doi:10.3390/children5070088.; Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United Sates. A policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3): 606–619. doi:10.1161/HHF.0b013e318291329a.; Rossano JW, Kim JJ, Decker JA, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail. 2012;18(6):459–470. doi:10.1016/j.cardfail.2012.03.001.; Nandi D, Lin KY, O’Connor MJ, et al. Hospital charges for pediatric heart failure related hospitalizations admissions in the United States from 2000 to 2009. Pediatr Cardiol. 2016;37(3):512–518. doi:10.1007/s00246-015-1308-0.; Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. doi:10.1002/ejhf.592.; Masarone D, Valente F, Rubino M, et al. Pediatric heart failure: a practical guide to diagnosis and management. Pediatr Neonatol. 2017;58(4):303–312. doi:10.1016/j.pedneo.2017.01.001.; Hinton RB, Ware SM. Heart failure in pediatric patients with congenital heart disease. Circ Res. 2017;120(6):978–994. doi:10.1161/CIRCRESAHA.116.308996.; Rhee EK, Canter CE, Basile S, et al. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome? J Heart Lung Transplant. 2007;26(5):447–452. doi:10.1016/j.healun.2007.02.005.; Schweiger M, Stiasny B, Dave H, et al. Cardiac transplantation in a neonate — first case in Switzerland and European overview. Clin Transplant. 2017;31 Issue 5: e12935. doi:10.1111/ctr.12935.; Goldfarb SB, Levvey BJ, Edwards LB, et al. The registry of the international society for heart and lung transplantation: nineteenth pediatric lung and heart-lung transplantation report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1196–1205. doi:10.1016/j.healun.2016.08.019.; Pfitzer C, Helm PC, Ferentzi H, et al. Changing prevalence of severe congenital heart disease: results from the national register for congenital heart defects in Germany. Congenit Heart Dis. 2017;12(6):787–793. doi:10.1111/chd.12515.; Kirklin JK. Current challenges in pediatric heart transplantation for congenital heart disease. Curr Opin Organ Transplant. 2015; 20(5):577–583. doi:10.1097/MOT.0000000000000238.; Dipchand AI. Current state of pediatric cardiac transplantation. Ann Cardiothorac Surg. 2018;7(1):31–55. doi:10.21037/acs.2018.01.07.; Caviedes Bottner P, Cordova Fernandez T, Larrain Valenzuela M, et al. [Dilated cardiomyopathy and severe heart failure. An update for pediatricians. (In English, Spanish).] Arch Argent Pediatr. 2018;116(3):e421–e428. doi:10.5546/aap.2018.eng.e421.; Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636–2648, 2648a–2648d. doi:10.1093/eurheartj/eht210.; Almond CS, Hoen H, Rossano JW, et аl.; Pediatric Heart Transplant Study (PHTS) Group Registry. Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation. J Heart Lung Transplant. 2018;37(4):441–450. doi:10.1016/j.healun.2017.03.013.; Becker P, Besa S, Riveros S, et al. [Results of a national program of pediatric heart transplantation: strengths and weakness. (In Spanish).] Rev Chil Pediatr. 2017;88(3):367–376. doi:10.4067/S0370-41062017000300009.; Raissadati A, Pihkala J, Jahnukainen T, et al. Late outcome after pediatric heart transplantation in Finland. Interact Cardiovasc Thorac Surg. 2016;23(1):18–25. doi:10.1093/icvts/ivw086.; Dipchand AI, Edwards LB, Kucheryavaya AY, et al. The registry of the International society for heart and lung transplantation: seventeenth official pediatric heart transplantation report-2014; focus theme: retransplantation.J Heart Lung Transplant. 2014; 33(10):985–995. doi:10.1016/j.healun.2014.08.002.; Rostad CA, Wehrheim K, Kirklin JK, et al. Bacterial infections after pediatric heart transplantation: epidemiology, risk factors and outcomes. J Heart Lung Transplant. 2017;36(9):996–1003. doi:10.1016/j.healun.2017.05.009.; Mahle WT, Fourshee MT, Naftel DM, et al. Does cytomegalovirus serology impact outcome after pediatric heart transplantation? J Heart Lung Transplant. 2009;28(12):1299–1305. doi:10.1016/j.healun.2009.07.011.; Трансплантация сердца. Национальные клинические рекомендации (утв. решением Координационного совета общероссийской общественной организации трансплантологов «Российское трансплантологическое общество» 29 ноября 2013 г. [интернет]. / Под ред. Готье С.В., Хомякова С.М., Арзуманова С.В., и др. — Российское трансплантологическое общество; 2013. Доступно по: https://freedocs.xyz/pdf-483241234. Ссылка активна на 12.01.2019.; Zablah JE, Everitt MD, Wilson N. Accelerated cardiac allograft vasculopathy after pediatric heart transplantation. Am J Transplantat. 2017;17:2983–2985. doi:10.1111/ajt.14475.; Miriuka SG, Langman LJ, Evrovski J, et al. Thromboembolism in heart transplantation: role of prothrombin G20210A and factor V Leiden. Transplantation. 2005;80(5):590–594. doi:10.1097/01.tp.0000170545.42790.6f.; Clemmensen TS, Holm NR, Eiskjær H, et al. ST elevation infarction after heart transplantation induced by coronary spasms and mural thrombus detected by optical coherence tomography. Case Rep Transplant. 2016;2016:1863869. doi:10.1155/2016/1863869.; Kobayashi D1, Du W, L’ecuyer TJ. Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients. Pediatr Transplant. 2013;17(5):436–440. doi:10.1111/petr.12095.; Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant. 2005; 24(1):63–66. doi:10.1016/j.healun.2003.10.013.; Greenway SC, Butts R, Naftel DC, et al. Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents. J Heart Lung Transplant. 2016;35(4): 457–465. doi:10.1016/j.healun.2015.10.040.; Fenton M, Mahmood A, Burch M, et al. Comparative study of pediatric coronary allograft vasculopathy between single centers in North America and United Kingdom. Transplant Proc. 2018;50(10): 3705–3709. doi:10.1016/j.transproceed.2018.06.022.; Castleberry C, Pruitt E, Ameduri R, et al. Risk stratification to determine the impact of induction therapy on survival, rejection and adverse events after pediatric heart transplant: A multiinstitutional study. J Heart Lung Transplant. 2018;37(4):458–466. doi:10.1016/j.healun.2017.05.010.; Carlo WF, Bryant R, Zafar F. Comparison of 10-year graft failure rates after induction with basiliximab or anti-thymocyte globulin in pediatric heart transplant recipients — the influence of race. Pediatr Transplant. 2019;8:e13366. doi:10.1111/petr.13366.; Rossano JW, Jefferies JL, Pahl E, et al. Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study Group. J Heart Lung Transplant. 2017;36(4):427–433. doi:10.1016/j.healun.2016.09.009.; Morgan CT, Manlhiot C, McCrindle BW, et al. outcome, incidence and risk factors for stroke after pediatric heart transplantation: an analysis of the international society for heart and lung transplantation registry. J Heart Lung Transplant. 2016;35(5): 597–602. doi:10.1016/j.healun.2016.01.1226.; Vanderlaan RD, Manlhiot C, Edwards LB, et al. Risk factors for specific causes of death following pediatric heart transplant: an analysis of the registry of the International Society of Heart and Lung Transplantation. Pediatr Transplant. 2015 Dec;19(8):896–905. doi:10.1111/petr.12594.; Sehgal S, Shea E, Kelm L, Kamat D. Heart transplant in children: what a primary care provider needs to know. Pediatr Ann. 2018;47(4):e172–e178. doi:10.3928/19382359-20180319-01.; https://vsp.spr-journal.ru/jour/article/view/2078

الاتاحة: https://vsp.spr-journal.ru/jour/article/view/2078
https://doi.org/10.15690/vsp.v18i2.2015

المؤلفون: O. V. Stukalova, A. A. Zhambeev, S. F. Sokolov, O. V. Sapelnikov, I. R. Grishin, V. G. Kiktev, N. B. Shlevkov, О. В. Стукалова, А. А. Жамбеев, С. Ф. Соколов, О. В. Сапельников, И. Р. Гришин, В. Г. Киктев, Н. Б. Шлевков

المصدر: Siberian Journal of Clinical and Experimental Medicine; Том 34, № 1 (2019); 39-47 ; Сибирский журнал клинической и экспериментальной медицины; Том 34, № 1 (2019); 39-47 ; 2713-265X ; 2713-2927 ; 10.29001/2073-8552-2019-34-1

مصطلحات موضوعية: кардиовертер-дефибриллятор, sudden cardiac death, ischemic cardiomyopathy, non-ischemic cardiomyopathy, magnetic resonance tomography of the heart, left ventricular fibrosis, QT dispersion, cardioverter-defibrillator, внезапная сердечная смерть, постинфарктный кардиосклероз, неишемическая кардиомиопатия, магнитно-резонансная томография сердца, фиброз левого желудочка, дисперсия интервала QT

وصف الملف: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/677/424; Velasco A., Stirrup J., Reyes E., Hage F.G. Guidelines in review: Comparison between AHA/ACC and ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J. Nucl. Cardiol. 2017;24:1893–1901.; Qu Z., Weiss J.N. Mechanisms of ventricular arrhythmias: from molecular fluctuations to electrical turbulence. Annu. Rev. Physiol. 2015;77:29–55. DOI:10.1146/annurev-physiol-021014-071622.; Waks J.W., Buxton A.E. Risk stratification for sudden cardiac death after myocardial infarction. Annu. Rev. Med. 2018;69:147–164.; Бокерия Л.А., Ревишвили А.Ш., Неминущий Н.М. Внезапная сердечная смерть. М.: ГЭОТАР-Медиа; 2011:267.; Santangeli P., Epstein A.E. Sudden cardiac death: lessons learned from cardiac implantable rhythm devices. Card. Electrophysiol. Clin. 2017;9:749–759.; Priori S.G., Blomström-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Europace. 2015;17:1601–1687.; Køber L., Thune J.J., Nielsen J.C., Haarbo J., Videbæk L., Korup E., et al. DANISH Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N. Engl. J. Med. 2016;375:1221–1230.; Стукалова О.В. Магнитно-резонансная томография сердца с отсроченным контрастированием — новый метод диагностики заболеваний сердца. REJR. 2013;3:7–17.; Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K., Kaul S., Laskey W.K., et al. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539–542.; Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005;18(12):1440–1463.; Zareba W., Moss A.J., Badilini F. Dispersion of repolarization: noninvasive marker of nonuniform recovery of ventricular excitability. In: Noninvasive Electrocardiology. Clinical Aspects of Holter Monitoring / eds. Moss A.J., Stern S. London: WB Saunders Co.;1996;405–419.; Huikuri H.V., Mäkikallio T.H., Raatikainen M.J., Perkiömäki J., Castellanos A., Myerburg R.J. Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation. 2003;108:110–115.; Huikuri H.V., Raatikainen M.J., Moerch-Joergensen R., Hartikainen J., Virtanen V., Boland J., et al. Cardiac Arrhythmias and Risk Stratification after Acute Myocardial Infarction (CARISMA) study group. Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur. Heart J. 2009;30:689–698.; Køber L., Thune J.J., Nielsen J.C., Haarbo J., Videbæk L., Korup E., et al. DANISH Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N. Engl. J. Med. 2016;375:1221– 1230.; Priori S.G., Blomström-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., et al. Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Europace. 2015;17:1601–1687.; Yan А., Shayne А., Brown К., Gupta S.N., Chan C.W., Luu T.M., et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32–39.; Yoshiga Y., Mathew S., Wissner E., Tilz R., Fuernkranz A., Metzner A., et al. Correlation between substrate location and ablation strategy in patients with ventricular tachycardia late after myocardial infarction. Heart Rhythm. 2012;9: 1192–1199. DOI:10.1016/j.hrthm.2012.03.058.; Culic V. Inferior myocardial infarction scars could be more arrhythmogenic than anterior ones. Europace. 2010;12:597. DOI:10.1093/europace/ eup445.; https://www.sibjcem.ru/jour/article/view/677

الاتاحة: https://www.sibjcem.ru/jour/article/view/677
https://doi.org/10.29001/2073-8552-2019-34-1-39-47

المؤلفون: Yu. Bunin A., S. Miklisanskaya A., V. Chigineva V., E. Zolozova A., Ю. Бунин А., С. Миклишанская В., В. Чигинева В., Е. Золозова А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 14, No 4 (2018); 605-611 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 4 (2018); 605-611 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-4

مصطلحات موضوعية: atrial fibrillation, ventricular arrhythmias, ST-segment elevation myocardial infarction, beta-blockers, amiodarone, pharmacological cardioversion, electrical cardioversion, implantable cardioverter-defibrillator, фибрилляция предсердий, желудочковые аритмии, инфаркт миокарда с подъемом сегмента ST, бета-адреноблокаторы, амиодарон, фармакологическая кардиоверсия, электроимпульсная терапия, имплантируемый кардиовертер-дефибриллятор

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1732/1698; 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting withST-segment elevation. Eur Heart J. 2018;39:119-77. doi:10.1093/eurheartj/ehx393.; Schmitt J., Duray G., Gersh B.J., Hohnloser S.H. Atrial fibrillation in acute myocardial infarction. Eur Heart J. 2009;30:1038-45. doi:10.1093/eurheartj/ehn579.; Jabre P., Jouven X., Adnet F. et al. Atrial fibrillation and death аfter myocardial infarction: a community study. Circulation. 2011;123:2094-100. doi:10.1161/CIRCULATIONAHA.110.990192.; Jabre P., Roder V.L., Murad M.H. et al. Mortality associated with atrial fibrillation in patients with myocardial infarction. Circulation. 2011;123:1587-93. doi.org/10.1161/CIRCULATIONAHA. 110.986661.; Crenshow B.S., Ward S.R., Granger C.B. et al. Atrial fibrillation in the setting of acute myocardial infarction. J Am Coll Cardiol. 1997;30:406-13.; Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA and EAPCI task force. Europace. 2014;16:1655-673. doi:10.1093/europace/euu208.; 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J. Am. Coll. Cardiol. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022.; 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-60. doi.org/10.1093/eurheartj/ehx419.; Risius T., Mortensen K., Schwermer T.F. et al.Comparison of anterio-lateral versus anterio-posterior electrode position for biphasic external cardioversion of atrial flutter. Am J Cardiol. 2009;104:154750. doi:10.1016/j.amjcard.2009.07.027.; Manegold J.C., Israel C.W., Ehrlich J.R. et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator. Eur Heart J. 2007;28:1731-8. doi:10.1093/eurheartj/ehm211.; Priori S.G., Blomstrom-Lundgvist C., Mazzanti A. et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2015;36:2793-867. doi:10.1093/europace/euv319.; Piccini J.P., Schulte P.J., Pieper K.S. et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med. 2011;39:78-83. doi:10.1097/CCM.0b013e3181fd6ad7.; He X.Z., Zhou S.H., Wan X.H. et al. The effect early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome. Clin Cardiol. 2011;34:59-63. doi:10.1002/clc.20818.; 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867. doi:10.1093/eurheartj/ ehv316.; 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127:e362-e425. doi:10.1161/CIR.0b013e3182742cf6.; Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-12. doi:10.1056/NEJM198908103210629.; The cardiac arrhythmia suppression trial II investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327(4):227-33. doi:10.1056/NEJM199207233270403.; Teo K.K., Yusuf S., Furberg C.D. Effects prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 1993;270(13):1589-95.; Antman E.M. ST-elevation myocardial infarction: management. In Braunwald E., Zipes L., Libby P., Bonow R. (eds). Heart disease. Philadelphia: W.B. Saunders company; 2005. P.1167-1226.; Бунин Ю.А. Возможности антиаритмической терапии в первичной профилактике смерти у больных с желудочковыми аритмиями. Рациональная Фармакотерапия в Кардиологии. 2010;6(6):870-5. doi:10.20996/1819-6446-2010-6-6-870-875.; Bardy G.H., Lee K.L., Mark D.B. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. doi:10.1056/NEJMoa043399.; Boutitie F., Boissel J.P., Connoly S.J. et al. Amiodarone interaction with beta-blokers: analysis of the merged EMIAT and CAMIAT detabases. Circulation. 1999;99:2268-75. doi:10.1161/01.CIR. 99.17.2268.; 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. ACC (2017). J Am Coll Cardiol. 2017 Oct 25. pii: S07351097(17)41306-4. doi:10.1016/j.jacc.2017.10.054.; https://www.rpcardio.com/jour/article/view/1732

الاتاحة: https://www.rpcardio.com/jour/article/view/1732
https://doi.org/10.20996/1819-6446-2018-14-4-605-611

المؤلفون: Vyacheslav A. Vostrikov, Artem N. Kuzovlev, В. А. Востриков, А. Н. Кузовлев

المصدر: General Reanimatology; Том 14, № 1 (2018); 58-67 ; Общая реаниматология; Том 14, № 1 (2018); 58-67 ; 2411-7110 ; 1813-9779 ; 10.15360/1813-9779-2018-1

مصطلحات موضوعية: автоматический наружный дефибриллятор, fibrillation, public-access defibrillation, automated external defibrillator, фибрилляция, общедоступная дефибрилляция

وصف الملف: application/pdf

Relation: https://www.reanimatology.com/rmt/article/view/1639/1177; Мороз В.В. (ред.). Рекомендации по проведению реанимационных мероприятий Европейского совета по реанимации (пересмотр 2015 г.). 3-е изд. М.: НИИОР, НСР; 2016: 192.; Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R., de Ferranti S.D., Floyd J., Fornage M., Gillespie C., Isasi C.R., Jiménez M.C., Jordan L.C., Judd S.E., Lackland D., Lichtman J.H., Lisabeth L., Liu S., Longenecker C.T., Mackey R.H., Matsushita K., Mozaffarian D., Mussolino M.E., Nasir K., Neumar R.W., Palaniappan L., Pandey D.K., Thiagarajan R.R., Reeves M.J., Ritchey M., Rodriguez C.J., Roth G.A., Rosamond W.D., Sasson C., Towfighi A., Tsao C.W., Turner M.B., Virani S.S., Voeks J.H., Willey J.Z., Wilkins J.T., Wu J.H., Alger H.M., Wong S.S., Muntner P.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017; 135 (10): e146– e603. DOI:10.1161/CIR.0000000000000485. PMID: 28122885; Gräsner J.T., Lefering R., Koster R.W., Masterson S., Böttiger B.W., Herlitz J., Wnent J., Tjelmeland I.B., Ortiz F.R., Maurer H., Baubin M., Mols P., Hadžibegovi I., Ioannides M., Škulec R., Wissenberg M., Salo A., Hubert H., Nikolaou N.I., Lóczi G., Svavarsdóttir H., Semeraro F., Wright P.J., Clarens C., Pijls R., Cebula G., Correia V.G., Cimpoesu D., Raffay V., Trenkler S., Markota A., Strömsöe A., Burkart R., Perkins G.D., Bossaert L.L.; EuReCa ONE Collaborators. EuReCa ONE-27 Nations, ONE Europe, ONE Registry: a prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe. Resuscitation. 2016; 105: 188– 195. DOI:10.1016/j.resuscitation.2016.06.004. PMID: 27321577; Handley A.J., Koster R., Monsieurs K., Perkins G.D., Davies S., Bossaert L.; European Resuscitation Council. European Resuscitation Council guidelines for resuscitation 2005. Section 2. Adult basic life support and use of automated external defibrillators. Resuscitation. 2005; 67 (Suppl 1): S7–S23. DOI:10.1016/j.resuscitation.2005.10.007. PMID: 16321717; Weisfeldt M.L., Everson-Stewart S., Sitlani C., Rea T., Aufderheide T.P., Atkins D.L., Bigham B., Brooks S.C., Foerster C., Gray R., Ornato J.P., Powell J., Kudenchuk P.J., Morrison L.J.; Resuscitation Outcomes Consortium Investigators. Ventricular tachyarrhythmias after cardiac arrest in public versus at home. N. Engl. J. Med. 2011; 364 (4): 313–321. DOI:10.1056/NEJMoa1010663. PMID: 21268723; Blom M.T., Beesems S.G., Homma P.C., Zijlstra J.A., Hulleman M., van Hoeijen D.A., Bardai A., Tijssen J.G., Tan H.L., Koster R.W. Improved survival after out-of-hospital cardiac arrest and use of automated external defibrillators. Circulation. 2014; 130 (21): 1868–1875. DOI:10.1161/CIRCULATIONAHA.114.010905. PMID: 25399395; Hulleman M., Berdowski J., de Groot J.R., van Dessel P.F., Borleffs C.J., Blom M.T., Bardai A., de Cock C.C., Tan H.L., Tijssen J.G., Koster R.W. Implantable cardioverter-defibrillators have reduced the incidence of resuscitation for out-of-hospital cardiac arrest caused by lethal arrhythmias. Circulation. 2012; 126 (7): 815–821. DOI:10.1161/CIRCULATIONAHA.111.089425. PMID: 22869841; van Diepen S., Girotra S., Abella B.S., Becker L.B., Bobrow B.J., Chan P.S., Fahrenbruch C., Granger C.B., Jollis J.G., McNally B., White L., Yannopoulos D., Rea T.D. Multistate 5-year initiative to improve care for out-of-hospital cardiac arrest: primary results from the Heart Rescue Project. J. Am. Heart. Assoc. 2017; 6 (9): pii: e005716. DOI:10.1161/JAHA.117.005716. PMID: 28939711; Nichol G., Thomas E., Callaway C.W., Hedges J., Powell J.L., Aufderheide T.P., Rea T., Lowe R., Brown T., Dreyer J., Davis D., Idris A., Stiell I.; Resuscitation Outcomes Consortium Investigators. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA. 2008; 300 (12): 1423–1431. DOI:10.1001/jama.300.12.1423. PMID: 18812533; Rajan S., Folke F., Hansen S.M., Hansen C.M., Kragholm K., Gerds T.A., Lippert F.K., Karlsson L., Møller S., Køber L., Gislason G.H., TorpPedersen C., Wissenberg M. Incidence and survival outcome according to heart rhythm during resuscitation attempt in out-of-hospital cardiac arrest patients with presumed cardiac etiology. Resuscitation. 2017; 114 (5): 157–163. DOI:10.1016/j.resuscitation.2016.12.021. PMID: 28087286; Stokes N.A., Scapigliati A., Trammell A.R., Parish D.C. The effect of the AED and AED programs on survival of individuals, groups and populations. Prehosp. Disaster Med. 2012; 27 (5): 419–424. DOI:10.1017/S1049023X12001197. PMID: 22985768; Meaney P.A., Nadkarni V.M., Kern K.B., Indik J.H., Halperin H.R., Berg R.A. Rhythms and outcomes of adult in-hospital cardiac arrest. Crit. Care Med. 2010; 38 (1): 101–108. DOI:10.1097/CCM.0b013e3181b43282. PMID: 19770741; Sandroni C., Nolan J., Cavallaro F., Antonelli M. In-hospital cardiac arrest: incidence, prognosis and possible measures to improve survival. Intensive Care Med. 2007; 33 (2): 237–245. DOI:10.1007/s00134-006-0326-z. PMID: 17019558; Girotra S., Nallamothu B.K., Spertus J.A., Li Y., Krumholz H.M., Chan P.S.; American Heart Association Get with the Guidelines–Resuscitation Investigators. Trends in survival after in-hospital cardiac arrest. N. Engl. J. Med. 2012; 367 (20): 1912–1920. DOI:10.1056/NEJMoa1109148. PMID: 23150959; Bergum D., Haugen B.O., Nordseth T., Mjølstad O.C., Skogvoll E. Recognizing the causes of in-hospital cardiac arrest — a survival benefit. Resuscitation. 2015; 97: 91–96. DOI:10.1016/j.resuscitation.2015.09.395. PMID: 26449872; Bergum D., Nordseth T., Mjølstad O.C., Skogvoll E., Haugen B.O. Causes of in-hospital cardiac arrest – incidences and rate of recognition. Resuscitation. 2015; 87: 63–68. DOI:10.1016/j.resuscitation.2014.11.007. PMID: 25434603; Nolan J.P., Soar J., Smith G.B., Gwinnutt C., Parrott F., Power S., Harrison D.A., Nixon E., Rowan K.; National Cardiac Arrest Audit. Incidence and outcome of in-hospital cardiac arrest in the United Kingdom. National Cardiac Arrest Audit. Resuscitation. 2014; 85 (8): 987–992. DOI:10.1016/j.resuscitation.2014.04.002. PMID: 24746785; Radeschi G., Mina A., Berta G., Fassiola A., Roasio A., Urso F., Penso R., Zummo U., Berchialla P., Ristagno G., Sandroni C.; Piedmont IHCA Registry Initiative. Incidence and outcome of in-hospital cardiac arrest in Italy: a multicentre observational study in the Piedmont Region. Resuscitation. 2017; 119: 48–55. DOI:10.1016/j.resuscitation.2017.06.020. PMID: 28655621; Caffrey S.L., Willoughby P.J., Pepe P.E., Becker L.B. Public use automated external defibrillators. N. Engl. J. Med. 2002; 347 (16): 1242–1247. DOI:10.1056/NEJMoa020932. PMID: 12393821; Hazinski M.F., Nadkarni V.M., Hickey R.W., O’Connor R., Becker L.B., Zaritsky A. Major changes in the 2005 AHA Guidelines for CPR and ECC: reaching the tipping point for change. Circulation. 2005; 112 (24 Suppl): IV206–IV211. DOI:10.1161/CIRCULATIONAHA.105.170809. PMID: 16314349; Кузовлев А.Н., Абдусаламов С.Н., Кузьмичев К.А. Оценка качества базовых и расширенных реанимационных мероприятий в многопрофильном стационаре (симуляционный курс). Общая реаниматология. 2016; 12 (6): 27-38. DOI:10.15360/1813-9779-2016- 6-27-38; Wissenberg M., Lippert F.K., Folke F., Weeke P., Hansen C.M., Christensen E.F., Jans H., Hansen P.A., Lang-Jensen T., Olesen J.B., Lindhardsen J., Fosbol E.L., Nielsen S.L., Gislason G.H., Kober L., Torp-Pedersen C. Association of national initiatives to improve cardiac arrest management with rates of bystander intervention and patient survival after out-ofhospital cardiac arrest. JAMA. 2013; 310 (13): 1377–1384. DOI:10.1001/jama.2013.278483. PMID: 24084923; Hasselqvist-Ax I., Riva G., Herlitz J., Rosenqvist M., Hollenberg J., Nordberg P., Ringh M., Jonsson M., Axelsson C., Lindqvist J., Karlsson T., Svensson L. Early cardiopulmonary resuscitation in out-of-hospital cardiac arrest. N. Engl. J. Med. 2015; 372 (24): 2307–2315. DOI:10.1056/NEJMoa1405796. PMID: 26061835; Weisfeldt M.L., Sitlani C.M., Ornato J.P., Rea T., Aufderheide T.P., Davis D., Dreyer J., Hess E.P., Jui J., Maloney J., Sopko G., Powell J., Nichol G., Morrison L.J.; ROC Investigators. Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consortium population of 21 million. J. Am. Coll. Cardiol. 2010; 55 (16): 1713–1720. DOI:10.1016/j.jacc.2009.11.077. PMID: 20394876; Agerskov M., Nielsen A.M., Hansen C.M., Hansen M.B., Lippert F.K., Wissenberg M., Folke F., Rasmussen L.S. Public Access Defibrillation: great benefit and potential but infrequently used. Resuscitation. 2015; 96: 53–58. DOI:10.1016/j.resuscitation.2015.07.021. PMID: 26234893; Lijovic M., Bernard S., Nehme Z., Walker T., Smith K.; Victorian Ambulance Cardiac Arrest Registry Steering Committee. Public access defibrillation— results from the Victorian Ambulance Cardiac Arrest Registry. Resuscitation. 2014; 85 (12): 1739–1744. DOI:10.1016/j.resuscitation.2014.10.005. PMID: 25449346; Kitamura T., Kiyohara K., Sakai T., Matsuyama T., Hatakeyama T., Shimamoto T., Izawa J., Fujii T., Nishiyama C., Kawamura T., Iwami T. Public-access defibrillation and out-of- hospital cardiac arrest in Japan. N. Engl. J. Med. 2016; 375 (17): 1649–1659. DOI:10.1056/NEJMsa1600011. PMID: 27783922; Ringh M., Rosenqvist M., Hollenberg J., Jonsson M., Fredman D., Nordberg P., Järnbert-Pettersson H., Hasselqvist-Ax I., Riva G., Svensson L. Mobilephone dispatch of laypersons for CPR in out-of-hospital cardiac arrest. N. Engl. J. Med. 2015; 372: 2316–2325. DOI:10.1056/NEJMoa1406038. PMID: 26061836; Folke F., Lippert F.K., Nielsen S.L., Gislason G.H., Hansen M.L., Schramm T.K., Sшrensen R., Fosbøl E.L., Andersen S.S., Rasmussen S., Køber L., TorpPedersen C. Location of cardiac arrest in a city center: strategic placement of automated external defibrillators in public locations. Circulation. 2009; 120 (6): 510–517. DOI:10.1161/CIRCULATIONAHA.108.843755. PMID: 19635969; Kudenchuk P.J., Redshaw J.D., Stubbs B.A., Fahrenbruch C.E., Dumas F., Phelps R., Blackwood J., Rea T.D., Eisenberg M.S. Impact of changes in resuscitation practice on survival and neurological outcome after out-of-hospital cardiac arrest resulting from nonshockable arrhythmias. Circulation. 2012; 125 (14): 1787–1794. DOI:10.1161/CIRCULATIONAHA.111.064873. PMID: 22474256; Steinberg M.T., Olsen J.A., Brunborg C., Persse D., Sterz F., Lozano M.Jr., Brouwer M.A., Westfall M., Souders C.M., van Grunsven P.M., Travis D.T., Lerner E.B., Wik L. Minimizing pre-shock chest compression pauses in a cardiopulmonary resuscitation cycle by performing an earlier rhythm analysis. Resuscitation. 2015; 87: 33–37. DOI:10.1016/j.resuscitation.2014.11.012. PMID: 25461493; Song K.J., Shin S.D., Park C.B., Kim J.Y., Kim D.K., Kim C.H., Ha S.Y., Eng Hock Ong M., Bobrow B.J., McNally B. Dispatcher-assisted bystander cardiopulmonary resuscitation in a metropolitan city: a before-after population-based study. Resuscitation. 2014; 85 (1): 34–41. DOI:10.1016/j.resuscitation.2013.06.004. PMID: 23792111; Forcina M.S., Farhat A.Y., O’Neil W.W., Haines D.E. Cardiac arrest survival after implementation of automated external defibrillator technology in the in-hospital setting. Crit. Care Med. 2009; 37 (4): 1229– 1236. DOI:10.1097/CCM.0b013e3181960ff3. PMID: 19326574; Smith R.J., Hickey B.B., Santamaria J.D. Automated external defibrillators and survival after in-hospital cardiac arrest: early experience at an Australian teaching hospital. Crit. Care Resusc. 2009; 11 (4): 261–265. PMID: 20001874; Smith R.J., Hickey B.B., Santamaria J.D. Automated external defibrillators and in-hospital cardiac arrest: patient survival and device performance at an Australian teaching hospital. Resuscitation. 2011; 82 (12): 1537–1542. DOI:10.1016/j.resuscitation.2011.06.025. PMID: 21741431; Chan P.S., Krumholz H.M., Spertus J.A., Jones P.G., Cram P., Berg R.A., Peberdy M.A., Nadkarni V., Mancini M.E., Nallamothu B.K.; American Heart Association National Registry of Cardiopulmonary Resuscitation (NRCPR) Investigators. Automated external defibrillators and survival after in-hospital cardiac arrest. JAMA. 2010; 304 (19): 2129–2136. DOI:10.1001/jama.2010.1576. PMID: 21078809; Gibbison B., Soar J. Automated external defibrillator use for in-hospital cardiac arrest is not associated with improved survival. Evid. Based Med. 2011; 16 (3): 95–96. DOI:10.1136/ebm1195. PMID: 21386118; Husain S., Eisenberg M. Police AED programs: a systematic review and meta-analysis. Resuscitation. 2013; 84 (9): 1184–1191. DOI:10.1016/j.resuscitation.2013.03.040. PMID: 23643893; Schober A., Sterz F., Laggner A.N., Poppe M., Sulzgruber P., Lobmeyr E., Datler P., Keferböck M., Zeiner S., Nuernberger A., Eder B., Hinterholzer G., Mydza D., Enzelsberger B., Herbich K., Schuster R., Koeller E., Publig T., Smetana P., Scheibenpflug C., Christ G., Meyer B., Uray T. Admission of out-of-hospital cardiac arrest victims to a high volume cardiac arrest center is linked to improved outcome. Resuscitation. 2016; 106: 42–48. DOI:10.1016/j.resuscitation.2016.06.021. PMID: 27368428; Elmer J., Rittenberger J.C., Coppler P.J., Guyette F.X., Doshi A.A., Callaway C.W.; Pittsburgh Post-Cardiac Arrest Service. Long-term survival benefit from treatment at a specialty center after cardiac arrest. Resuscitation. 2016; 108: 48–53. DOI:10.1016/j.resuscitation.2016.09.008. PMID: 27650862; https://www.reanimatology.com/rmt/article/view/1639

الاتاحة: https://www.reanimatology.com/rmt/article/view/1639
https://doi.org/10.15360/1813-9779-2018-1-58-67